The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsSarah V. Holt, Paul D. Smith, Armelle Logié et al.|British Journal of Cancer|2012Cited by 111
Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)Sarah V. Holt, Paul D. Smith, Yi Gu et al.|Cancer Research|2012Cited by 86
Supplementary Methods from Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)Sarah V. Holt, Paul D. Smith, Armelle Logié et al.|Unknown|2023Cited by 0
Data from Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)Sarah V. Holt, Paul D. Smith, Armelle Logié et al.|Unknown|2023Cited by 0
Data from Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)Sarah V. Holt, Paul D. Smith, Armelle Logié et al.|Unknown|2023Cited by 0